Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2005

View Archived Issues

Rylomine induces analgesic effects in patients with postsurgical orthopedic pain

Celldex Therapeutics acquires Lorantis and assets of Alteris Therapeutics

OGX-011 begins new phase II study in prostate cancer

GPI-0100 adjuvant licensed by Hawaii Biotech

Osiris to begin phase II study of Prochymal for severe GVHD

Arrowhead Research accelerates investment in Insert Therapeutics

Trexima NDA accepted for review

IND filing for MEDI-545 for lupus

RTA-401 cleared for clinical testing

KP-1461 begins phase Ib study for HIV

Talabostat begins phase III for metastatic NSCLC

CHIR-12.12 enters phase I study for multiple myeloma

Inspire completes studies prior to end-of-phase II meeting

Mack and Transport enter agreement for cold sores device/drug product

Aerie closes Series A financing

Phase III program under way for Memryte implant

Benefits of rHuPH20 for cerebral brain ischemia and enhanced pharmacokinetics

M-475271 antitumor effects via inhibition of angiogenesis

Targeting CIDS for CNS injury: a new avenue for therapeutic investigation

New PDE inhibitors disclosed by Altana

Janssen patent claims new opioid receptor agonists for pain

Novel anti-HIV agents reported in recent patent literature

LY-456236 produces anticonvulsant effects in preclinical testing

New data on the metabolic effects of orexin A

Oral insulin prevents postprandial glucose excursions in patients with type 1 diabetes

Pioglitazone improves cardiovascular outcome in patients with type 2 diabetes

Update on the antibacterial efficacy of tigecycline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.